The FDA is looking at the data here. The reason for these talks are so that the design can be adjusted and agreed upon, so that it will provide the best data. This is normally the responsibility of statisticians and not normally field experts. Trust me, we want this meeting. Yes it adds time, but people forget this company is doing a lot with very little. FDA timelines take a long time and are out of our control, period. 3-6 months is neither here or there.
On a separate note:
Not saying this is you, but many on this board often expect too much and don’t understand timelines, either that or are just impatient. I know some have been invested in this company for a long time, but that’s the business of drug commercialization. Great science or not, it takes time, if you didn’t know that coming into it this investment, now you do. Yes we are strapped for cash, yes NP is not the same caliber of a Fortune 500 CEO, and yes further dilution (small or big) will occur. However, I think the science is sound and a buyout is inevitable (or partnerships) after we receive some 1Q/1H sales numbers or who knows maybe before. Big companies like to make bets on small clinical Pharma, but they love to invest heavily in companies that have solid and growing revenue streams. Our stock price is low and on the OTC to boot, they could come in at a moments notice, but they are waiting us out because they can... there is a high price tag on this company, no one wants to foot the bill yet. At the same time we are way below the price tag Gilead is willing to pay, so they will reduce risk and wait. The day will come for a massive partnership or BO, I believe.
As for the people saying to stop focusing on other indications.... please stop the non-sense. More indications mean more options for future revenue or a higher buyout valuation.
I firmly believe we are sitting on a diamond in the rough. This is the home stretch people, stay positive and stay patient.
On a separate note:
Not saying this is you, but many on this board often expect too much and don’t understand timelines, either that or are just impatient. I know some have been invested in this company for a long time, but that’s the business of drug commercialization. Great science or not, it takes time, if you didn’t know that coming into it this investment, now you do. Yes we are strapped for cash, yes NP is not the same caliber of a Fortune 500 CEO, and yes further dilution (small or big) will occur. However, I think the science is sound and a buyout is inevitable (or partnerships) after we receive some 1Q/1H sales numbers or who knows maybe before. Big companies like to make bets on small clinical Pharma, but they love to invest heavily in companies that have solid and growing revenue streams. Our stock price is low and on the OTC to boot, they could come in at a moments notice, but they are waiting us out because they can... there is a high price tag on this company, no one wants to foot the bill yet. At the same time we are way below the price tag Gilead is willing to pay, so they will reduce risk and wait. The day will come for a massive partnership or BO, I believe.
As for the people saying to stop focusing on other indications.... please stop the non-sense. More indications mean more options for future revenue or a higher buyout valuation.
I firmly believe we are sitting on a diamond in the rough. This is the home stretch people, stay positive and stay patient.
4
1
